Literature DB >> 30430396

Opioidergic Agents as Antidepressants: Rationale and Promise.

Parnika P Saxena1, J Alexander Bodkin2,3.   

Abstract

Research concerning psychiatric issues relating to opioid drugs currently focuses primarily on their role in reinforcing addictive behaviors, given the recent proliferation of lethal abuse of illicit opiates in the United States and around the world. In contrast, this article will review the mechanism of action of opioids in affective disorders and the available evidence and potential for their use, especially in the treatment of resistant major depression. Buprenorphine is the opioid derivative of special interest; we review this and other opioid derivatives, highlighting the growing role of opioids in treating depressive illnesses and other related psychopathologies.

Entities:  

Year:  2019        PMID: 30430396     DOI: 10.1007/s40263-018-0584-7

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  51 in total

Review 1.  Mu opioid receptor: a gateway to drug addiction.

Authors:  Candice Contet; Brigitte L Kieffer; Katia Befort
Journal:  Curr Opin Neurobiol       Date:  2004-06       Impact factor: 6.627

2.  Buprenorphine responders.

Authors:  L Mongan; E Callaway
Journal:  Biol Psychiatry       Date:  1990-12-15       Impact factor: 13.382

3.  Depressive symptoms during buprenorphine treatment of opioid abusers.

Authors:  T R Kosten; C Morgan; T A Kosten
Journal:  J Subst Abuse Treat       Date:  1990

4.  Opiate receptor: demonstration in nervous tissue.

Authors:  C B Pert; S H Snyder
Journal:  Science       Date:  1973-03-09       Impact factor: 47.728

5.  Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.

Authors:  Maurizio Fava; Asli Memisoglu; Michael E Thase; J Alexander Bodkin; Madhukar H Trivedi; Marc de Somer; Yangchun Du; Richard Leigh-Pemberton; Lauren DiPetrillo; Bernard Silverman; Elliot Ehrich
Journal:  Am J Psychiatry       Date:  2016-02-12       Impact factor: 18.112

6.  Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial.

Authors:  Yoram Yovell; Gali Bar; Moti Mashiah; Yehuda Baruch; Irina Briskman; Jack Asherov; Amit Lotan; Amihai Rigbi; Jaak Panksepp
Journal:  Am J Psychiatry       Date:  2015-12-18       Impact factor: 18.112

Review 7.  Psychotherapeutic benefits of opioid agonist therapy.

Authors:  Peter L Tenore
Journal:  J Addict Dis       Date:  2008

8.  Buprenorphine treatment of refractory depression.

Authors:  J A Bodkin; G L Zornberg; S E Lukas; J O Cole
Journal:  J Clin Psychopharmacol       Date:  1995-02       Impact factor: 3.153

Review 9.  Relationship of neurotransmitters to the symptoms of major depressive disorder.

Authors:  David J Nutt
Journal:  J Clin Psychiatry       Date:  2008       Impact factor: 4.384

10.  Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.

Authors:  Jordan F Karp; Meryl A Butters; Amy E Begley; Mark D Miller; Eric J Lenze; Daniel M Blumberger; Benoit H Mulsant; Charles F Reynolds
Journal:  J Clin Psychiatry       Date:  2014-08       Impact factor: 4.384

View more
  3 in total

1.  Low-Dose Tramadol as an Off-Label Antidepressant: A Data Mining Analysis from the Patients' Perspective.

Authors:  John A Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-29

2.  Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder.

Authors:  Andrew D Peckham; Margaret L Griffin; R Kathryn McHugh; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2020-06-12       Impact factor: 4.492

3.  Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder.

Authors:  Anna Beth Parlier-Ahmad; Mickeal Pugh; Caitlin E Martin
Journal:  J Racial Ethn Health Disparities       Date:  2021-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.